Get the Stockscreener App
1.2991
2.80%
0.0491
Enveric Biosciences Inc stock is traded at $1.2991, with a volume of 53,987.
It is up +2.80% in the last 24 hours and down -1.15% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
53,987
Relative Volume:
0.29
Market Cap:
$3.16M
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-0.2024
EPS:
-6.42
Net Cash Flow:
$-11.56M
1W Performance:
+4.47%
1M Performance:
-1.15%
6M Performance:
-73.72%
1Y Performance:
-87.23%
1-Day Range:
$1.2436
$1.31
1-Week Range:
$1.18
$1.31
52-Week Range:
$1.01
$11.55
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Compare ENVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.285 | 3.16M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.23 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.34 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.29 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.42 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences Announces Participation in 2025 BIO International Convention | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Participation in 2025 BIO International Convention - Business Wire
Enveric Biosciences Receives Notice Of Allowance For New Class Of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders - marketscreener.com
Enveric Biosciences Receives Notice of Allowance for New Class o - GuruFocus
Enveric Biosciences (ENVB) Gains Patent Approval for Innovative Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders | ENVB Stock News - GuruFocus
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders - Yahoo Finance
Enveric Receives U.S. Patent for Sleep, CNS Therapeutics - Insider Monkey
Enveric’s Patent Win Targets New Frontiers in Sleep Medicine - microdose.buzz
Enveric Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeu - GuruFocus
Enveric Biosciences Receives New US Patent on Molecules for Central Nervous System, Sleep Therapeutics - marketscreener.com
Enveric Biosciences secures patent for sleep disorder molecules By Investing.com - Investing.com Nigeria
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeutic Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds - Yahoo Finance
Enveric Biosciences announces results from EB-003 trial - Yahoo Finance
Enveric’s EB-003 shows statistically significant improvements in model of severe chronic depression - BioWorld MedTech
Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003 - marketscreener.com
Enveric Biosciences reports breakthrough in depression model By Investing.com - Investing.com India
Enveric Biosciences (ENVB) Reports Promising Preclinical Results - GuruFocus
Enveric Biosciences reports breakthrough in depression model - Investing.com Australia
Enveric Biosciences (ENVB) Reports Promising Preclinical Results for EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ:ENVB) Stock Price Down 0.8% – Here’s Why - Defense World
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease - marketscreener.com
Enveric Biosciences Stakes Its Claim in Neurodegeneration Market - microdose.buzz
Enveric Biosciences files provisional patent for new molecules By Investing.com - Investing.com Canada
Enveric Biosciences Identifies Neuroplastogen Candidates with Po - GuruFocus
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerative Drug Patent | ENVB Stock News - GuruFocus
Enveric Biosciences files new provisional patent application - TipRanks
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results - BioSpace
Enveric Biosciences Reports First Quarter 2025 Financial and Cor - GuruFocus
Enveric Biosciences (ENVB) Projected to Post Earnings on Tuesday - Defense World
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Enveric Biosciences (NASDAQ:ENVB) Trading Down 1% – Here’s Why - Defense World
Enveric Biosciences appoints new accounting firm - Investing.com India
Enveric Biosciences appoints new accounting firm By Investing.com - Investing.com South Africa
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges - Investing.com Canada
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges By Investing.com - Investing.com South Africa
Psychedelic: Enveric, Filament Health report earnings results - TipRanks
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - BioSpace
Enveric posts $9.5M loss for 2024, but revenue could be on horizon with licensing deals - Green Market Report
Enveric Lands Massive $184M Biotech Licensing Deals as EB-003 Shows Promise - Stock Titan
Enveric Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Enveric Biosciences, Inc. SEC 10-K Report - TradingView
Enveric Biosciences Inc. (ENVB) reports earnings - qz.com
Enveric Biosciences Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):